Shree Ganesh Biotech (India) Ltd (SHREEGANES) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Shree Ganesh Biotech (India) Ltd stock ₹0.21, price ₹0.44, upside -52.3%, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 24, 2026.
How to read this chart
60‑month range ₹0.4400 – ₹9.64 · fair‑value band ₹0.1600 – ₹0.2600 · the ₹0.4400 price screens above the ₹0.2100 fair value. Dashed = 300-day average. As of Oct 24, 2026.
Follow Shree Ganesh Biotech (India) in your weekly email
Every Wednesday you see whether Shree Ganesh Biotech (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shree Ganesh Bio-Tech (India) Limited engages in plant tissue culture activities in India. The company trades seeds and bhushi. It also engages in production, processing, and marketing of hybrid seeds for various crops, including corn, sunflower, cotton, paddy, grain, and sorghum.
Show moreShow less
The company was incorporated in 1982 and is based in Kolkata, India.
Stock analysis
Shree Ganesh Biotech (India) Ltd (SHREEGANES) currently trades at ₹0.4400, while our model-based Fair Value estimate is ₹0.2100, 52.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of ₹0.9000 per share, and 2 of the 7 models we run sit above the ₹0.4400 price.
Bear case: the Earnings-Based group reads lowest at ₹0.1000, and 5 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹0.1600 (bear) to ₹0.2600 (bull), the price of ₹0.4400 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shree Ganesh Biotech (India) Ltd reported revenue of ₹49.7M in FY2026 versus ₹726M in FY2022, a compound −48.9%/yr. Reported net income was ₹3.8M in FY2026, compounding −37.8%/yr from FY2022.
Key figures
Market cap ₹175M (≈ $1.8M) Micro · P/E ratio 56.0 · P/S ratio 4.25 · EPS (TTM) ₹−0.0100 · Net margin −10.4% · Return on equity 0.6% · Return on assets (EBIT) 0.6% · Operating margin −62.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 22% fair-value upside, at −52%, SHREEGANES screens richer than that median.
Fair Value models
Bear₹0.1600Fair Value ₹0.2100Bull₹0.2600
Price ₹0.4400 · Upside -52.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−78.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−57.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.0%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → −19%
Compare Shree Ganesh Biotech (India) Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks
Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−58.2% · Bottom 25%
Profitability
Return on equity (12 months)0.6% · Bottom 25%
Return on assets0.6% · Bottom 25%
Net margin (12 months)−10.4% · Bottom 25%
Operating margin (12 months)−62.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)3.3% · Below median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
P/E (12 months)56.0× · Priciest 25%
P/B0.28× · Cheapest 25%
P/S (12 months)3.50× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 32
FUTURE (revenue growth)17· sector 27
PAST (return on equity)2· sector 30
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Shree Ganesh Biotech (India) Ltd (SHREEGANES) overvalued or undervalued?
As of Oct 24, 2026, our model estimates a fair value of ₹0.2100 versus a price of ₹0.4400, about −52% upside (overvalued).
What is the fair value of SHREEGANES?
Our model-based fair value for Shree Ganesh Biotech (India) Ltd is ₹0.2100 (as of Oct 24, 2026), built from audited fundamentals. The current price: ₹0.4400.
What is the quality score of SHREEGANES?
Shree Ganesh Biotech (India) Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Our model-based price target is the fair value of ₹0.2100 (as of Oct 24, 2026) from 7 valuation models. Cautious scenario ₹0.1600, optimistic scenario ₹0.2600. It is a calculation from audited fundamentals, not an analyst target.
What is the Shree Ganesh Biotech (India) Ltd stock forecast for 2026?
Our models put fair value at ₹0.2100, about −52% upside versus a price of ₹0.4400 (overvalued). Cautious scenario ₹0.1600, optimistic scenario ₹0.2600. The calculation is refreshed regularly with new filings.
What is the revenue of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Shree Ganesh Biotech (India) Ltd reported trailing-twelve-month revenue of about ₹50.2M (latest available figure, as of Oct 24, 2026).
What is the intrinsic value of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shree Ganesh Biotech (India) Ltd it is ₹0.2100 per share (as of Oct 24, 2026), against a price of ₹0.4400. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Shree Ganesh Biotech (India) Ltd stock overvalued or undervalued in 2026?
As of Oct 24, 2026, SHREEGANES trades above its calculated fair value: price ₹0.4400, fair value ₹0.2100, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SHREEGANES?
No. The price is what the market pays today (₹0.4400); the fair value is what the company's own numbers justify (₹0.2100). For Shree Ganesh Biotech (India) Ltd the two are ₹0.2300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shree Ganesh Biotech (India) Ltd worth?
The market values Shree Ganesh Biotech (India) Ltd at about ₹175M (market capitalisation, as of Oct 24, 2026). Per share that is ₹0.4400; our models calculate a fair value of ₹0.2100 per share.
What do the bullish and bearish scenarios say about SHREEGANES?
Our models span a range for Shree Ganesh Biotech (India) Ltd: cautious scenario ₹0.1600, base ₹0.2100, optimistic ₹0.2600 per share (as of Oct 24, 2026, price ₹0.4400). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SHREEGANES?
Shree Ganesh Biotech (India) Ltd trades at a price-to-earnings ratio of 56.0 (as of Oct 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹0.2100 is built from several models across several years. Other multiples: P/B 0.3, P/S 3.5.
How solid is the balance sheet of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Balance-sheet figures for Shree Ganesh Biotech (India) Ltd (as of Oct 24, 2026): return on equity 0.6%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is SHREEGANES from its 52-week high?
Shree Ganesh Biotech (India) Ltd trades at ₹0.4400, about 41% below its 52-week high of ₹0.7500 and at the low of ₹0.4400 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.2100 is for.
Which stocks are comparable to Shree Ganesh Biotech (India) Ltd?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shree Ganesh Biotech (India) Ltd stock attractive at the current price?
The data as of Oct 24, 2026: price ₹0.4400, calculated fair value ₹0.2100 (−52%), Quality Score 52/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SHREEGANES calculated?
We run Shree Ganesh Biotech (India) Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹0.2100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Shree Ganesh Biotech (India) Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The closing price on Oct 23, 2026 was ₹0.4400. Our model-based fair value is ₹0.2100, about −52% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shree Ganesh Biotech (India) Ltd right now?
The price sits above even our optimistic bull case (₹0.2600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shree Ganesh Biotech (India) Ltd
How large is the market capitalisation of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The market capitalisation of Shree Ganesh Biotech (India) Ltd is ₹175M (≈ $1.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The price-to-sales ratio of Shree Ganesh Biotech (India) Ltd is 4.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Earnings per share at Shree Ganesh Biotech (India) Ltd are ₹−0.0100 (price ÷ EPS = P/E 56.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The net margin of Shree Ganesh Biotech (India) Ltd is −10.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The return on equity (ROE) of Shree Ganesh Biotech (India) Ltd is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
On an EBIT basis the return on assets of Shree Ganesh Biotech (India) Ltd is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
The operating margin of Shree Ganesh Biotech (India) Ltd is −62.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Revenue at Shree Ganesh Biotech (India) Ltd is growing +3.3% versus a year earlier (3y avg −57.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shree Ganesh Biotech (India) Ltd (SHREEGANES)?
Earnings per share at Shree Ganesh Biotech (India) Ltd are growing −51.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shree Ganesh Biotech (India) Ltd (SHREEGANES) generate?
The free cash flow of Shree Ganesh Biotech (India) Ltd is −₹82.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shree Ganesh Biotech (India) Ltd (SHREEGANES) carry?
The net debt of Shree Ganesh Biotech (India) Ltd is ₹1.7M (fiscal year 2021). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shree Ganesh Biotech (India) Ltd in the live analysis
One click puts Shree Ganesh Biotech (India) Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 24, 2026